Press Releases

Date Title
9/29/22 Sarepta Therapeutics Submits Biologics License Application for SRP-9001 for the Treatment of Ambulant Patients with Duchenne Muscular Dystrophy
9/14/22 Sarepta Therapeutics Prices $1.0 Billion of Convertible Senior Notes Due 2027
9/12/22 Sarepta Therapeutics Announces Proposed Offering of $1.0 Billion of Convertible Senior Notes Due 2027
9/7/22 Sarepta Therapeutics Anuncia a los Destinatarios de Route 79, el Programa de Becas de Duchenne, para el Año Académico 2022-2023
9/7/22 Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2022-2023 Academic Year
9/6/22 Sarepta Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
9/6/22 Sarepta Therapeutics Announces That FDA has Lifted its Clinical Hold on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy
8/31/22 Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
8/8/22 Sarepta Therapeutics Announces Progress on the MyoAAV Program and Exclusive Licensing Agreement with The Broad Institute for MyoAAV Next-generation Capsids for Rare Genetic Diseases
8/2/22 Sarepta Therapeutics Announces Second Quarter 2022 Financial Results and Recent Corporate Developments
Displaying 31 - 40 of 776